Abstract
Background Brain-derived neurotrophic factor (BDNF) plays an important role in the regulation of synaptic plasticity and neurotransmitter release across multiple neurotransmitter systems. Recent studies have suggested that BDNF plays a role in the pathogenesis of psychiatric symptoms in patients with systemic lupus erythematosus (SLE). Objectives We hypothesized that the polymorphism of BDNF Val66Met is associated with the emergence of psychiatric symptoms (PS) and serum BDNF levels in SLE patients. To examine the hypothesis, we compared the BDNF Val66Met polymorphism and serum BDNF levels in patients with SLE with or without PS. Methods Psychiatric symptoms were assessed in 54 patients with SLE. PS were evaluated using the Brief Psychiatric Rating Scale. Genotyping was carried out using a 54-nuclease assay. Serum BDNF levels were measured by using enzyme-linked immunosorbent assay. Results The presence of the Met allele was not significantly associated with the presence of PS or with serum BDNF levels in patients with SLE. Conclusion Our data do not support the common variant Val66Met of the BDNF gene as an etiologic factor in the various forms of PS and serum BDNF levels in SLE.
| Original language | English |
|---|---|
| Pages (from-to) | 348-351 |
| Number of pages | 4 |
| Journal | Human Psychopharmacology |
| Volume | 26 |
| Issue number | 4-5 |
| DOIs | |
| Publication status | Published - 01-06-2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
}
No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients. / Ikenouchi-Sugita, Atsuko; Yoshimura, Reiji; Kishi, Taro; Umene-Nakano, Wakako; Hori, Hikaru; Katsuki, Asuka; Saito, Kazuyoshi; Iwata, Nakao; Tanaka, Yoshiya; Nakamura, Jun.
In: Human Psychopharmacology, Vol. 26, No. 4-5, 01.06.2011, p. 348-351.Research output: Contribution to journal › Article
TY - JOUR
T1 - No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients
AU - Ikenouchi-Sugita, Atsuko
AU - Yoshimura, Reiji
AU - Kishi, Taro
AU - Umene-Nakano, Wakako
AU - Hori, Hikaru
AU - Katsuki, Asuka
AU - Saito, Kazuyoshi
AU - Iwata, Nakao
AU - Tanaka, Yoshiya
AU - Nakamura, Jun
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Background Brain-derived neurotrophic factor (BDNF) plays an important role in the regulation of synaptic plasticity and neurotransmitter release across multiple neurotransmitter systems. Recent studies have suggested that BDNF plays a role in the pathogenesis of psychiatric symptoms in patients with systemic lupus erythematosus (SLE). Objectives We hypothesized that the polymorphism of BDNF Val66Met is associated with the emergence of psychiatric symptoms (PS) and serum BDNF levels in SLE patients. To examine the hypothesis, we compared the BDNF Val66Met polymorphism and serum BDNF levels in patients with SLE with or without PS. Methods Psychiatric symptoms were assessed in 54 patients with SLE. PS were evaluated using the Brief Psychiatric Rating Scale. Genotyping was carried out using a 54-nuclease assay. Serum BDNF levels were measured by using enzyme-linked immunosorbent assay. Results The presence of the Met allele was not significantly associated with the presence of PS or with serum BDNF levels in patients with SLE. Conclusion Our data do not support the common variant Val66Met of the BDNF gene as an etiologic factor in the various forms of PS and serum BDNF levels in SLE.
AB - Background Brain-derived neurotrophic factor (BDNF) plays an important role in the regulation of synaptic plasticity and neurotransmitter release across multiple neurotransmitter systems. Recent studies have suggested that BDNF plays a role in the pathogenesis of psychiatric symptoms in patients with systemic lupus erythematosus (SLE). Objectives We hypothesized that the polymorphism of BDNF Val66Met is associated with the emergence of psychiatric symptoms (PS) and serum BDNF levels in SLE patients. To examine the hypothesis, we compared the BDNF Val66Met polymorphism and serum BDNF levels in patients with SLE with or without PS. Methods Psychiatric symptoms were assessed in 54 patients with SLE. PS were evaluated using the Brief Psychiatric Rating Scale. Genotyping was carried out using a 54-nuclease assay. Serum BDNF levels were measured by using enzyme-linked immunosorbent assay. Results The presence of the Met allele was not significantly associated with the presence of PS or with serum BDNF levels in patients with SLE. Conclusion Our data do not support the common variant Val66Met of the BDNF gene as an etiologic factor in the various forms of PS and serum BDNF levels in SLE.
UR - http://www.scopus.com/inward/record.url?scp=79960841789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960841789&partnerID=8YFLogxK
U2 - 10.1002/hup.1203
DO - 10.1002/hup.1203
M3 - Article
C2 - 21678493
AN - SCOPUS:79960841789
VL - 26
SP - 348
EP - 351
JO - Human Psychopharmacology
JF - Human Psychopharmacology
SN - 0885-6222
IS - 4-5
ER -